Pulmonary hypertension: Characterization based on the experience of reference centers;"Hipertensão pulmonar: Caracterização baseada na experiência de centros de referência"

Revista da Associacao Medica Brasileira

Volumn 52, Issue 3, 2006, Pages 127-129

  Tuder, Rubin M ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EDITORIAL; HOSPITALIZATION; HUMAN; PATHOLOGY; PULMONARY HYPERTENSION;

HUMANS; HYPERTENSION, PULMONARY; SEVERITY OF ILLNESS INDEX;

EID: 33746327789     PISSN: 01044230     EISSN: None     Source Type: Journal    
DOI: 10.1590/S0104-42302006000300003     Document Type: Editorial

References (18)

1. Tuder RM, Cool CD, Jennings C et al. Pulmonary vascular involvement in interstitial lung disease. In: Schwartz SM, King TEJ, editors. Interstitial lung disease. Hamilton: B.C. Decker; 1998. p.251-63.
2. Lapa MS, Ferreira EVM, Jardim C, Martins BCS, Arakaki JSO, Souza R. Caracteristicas clinicas dos pacientes com hipertensao pulmonar em dois centros de referencia em Sao Paulo. Rev Assoc Med Bras 2006; 52(3):144-7.
3. Zaiman A, Fijalkowska I, Hassoun PM, Tuder RM. One hundred years of research in the pathogenesis of pulmonary hypertension. Am J Respir Cell Mol Biol 2005;33:425-31.
4. Simonneau G, Galie N, Rubin LJ, Seeger W, Domenighetti G, Gibb S, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004;43(12 Suppl 1):S5-S12.
5. Chazova I, Loyd JE, Newman JH, Zhdanov VS, Belenkov Y, Meyrick B, et al. Pulmonary artery adventitial changes and venous involvement in primary pulmonary hypertension. Am J Pathol 1995;146:389-97.
6. Santos S, Peinado VI, Ramirez J, Melgoza T, Roca J, Rodriguez-Roisin R, et al. Characterization of pulmonary vascular remodelling in smokers and patients with mild COPD. Eur Resp J 2002;19:632-38.
7. Tuder RM, Zaiman AL. Pathology of pulmonary vascular disease. In: Peacock A, Rubin LJ, editors. Pulmonary circulation. London: Hodder Arnold, Health Sciences; 2003.
8. Tuder RM, Groves BM, Badesch DB, Voelkel NF. Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. Am J Pathol 1994;144:275-85.
9. Lee SD, Shroyer KR, Markham NE, Cool CD, Voelkel NF, Tuder RM. Monoclonal endothelial cell proliferation is present in primary but not secondary pulmonary hypertension . J Clin Invest 1998;101:927-34.
10. Yeager ME, Halley GR, Golpon HÁ, Voelkel NF, Tuder RM. Microsatellite instability of endothelial cell growth and apoptosis genes within plexiform lesions in primary pulmonary hypertension. Circ Res 2001;88:e8-e11.
11. Lane KB, Machado RD, Pauciulo MW, Thomson JR, Phillips JÁ 3rd, Loyd JE, et al. Heterozygous germline mutations in BMPR2 encoding a TGF-B receptor cause familiar pulmonary hypertension. Nat Genet 2000;26:81-4.
12. Deng Z, Morse JH, Slager SL, Cuervo N, Moore KJ, Venetos G, et al. Familial primary pulmonary hypertension (Gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am J Hum Genet 2000;67:737-44.
13. Voelkel NF, Cool CD, Lee SD, Wright L, Geraci MW, Tuder RM. Primary pulmonary hypertension between inflammation and cancer. Chest 1999;114(1 Suppl):225S-30S.
14. Bull TM, Golpon H, Hebbel RP, Solovvey A, Cool CD, Tuder RM, et al. Circulating endothelial cells in pulmonary hypertension. Thomb Haemost 2003;90:698-703.
15. Bull TM, Coldren CD, Moore M, Sotto-Santiago SM, Pham DV, Nana-Sinkam SP, et al. Gene microarray analysis of peripheral blood cells in pulmonary arterial hypertension. Am J Respir Crit Care Med 2004;170:911-9.
16. Schermuly RT, Dony E, Ghofrani HÁ, Pullamsetti S, Savai R, Roth M, et al. Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest 2005;115:2811-21.
17. Ghofrani HA, Seeger W, Grimminger F. Imatinib for the treatment of pulmonary arterial hypertension. N Engl J Med 2005;353:1412-3.
18. Zhao YDD, Courtman DW, Deng YP, Kugathasan L, Zhang Q, Stewart DJ, et al. Rescue of monocrotaline-induced pulmonary arterial hypertension using bone marrow-derived endothelial-like progenitor cells - Efficacy of combined cell and eNOS gene therapy in established disease. Circ Res 2005;96:442-50.